SCHEMBL1480463

SCHEMBL1480463

CCOc1ccc(-c2ccc(C=Cc3nc(-c4ccc(Cl)cc4Cl)c[nH]3)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.41
KDM4E B2RXH2 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
TRPV1 Q8NER1 1/20 0.40
APP P05067 1/20 0.39
PRKAB2 O43741 2/20 0.39
PRKAG1 P54619 2/20 0.39
PRKAA2 P54646 2/20 0.39
PRKAA1 Q13131 2/20 0.39
PRKAG3 Q9UGI9 2/20 0.39
PRKAG2 Q9UGJ0 2/20 0.39
PRKAB1 Q9Y478 2/20 0.39
RELA Q04206 1/20 0.39
MAOB P27338 1/20 0.38
ESR1 P03372 2/20 0.38
AHR P35869 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
TP53 P04637 2/20 0.37
XDH P47989 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1480461 1.00 MAPT (0.41) MAPTKDM4ETDP1TRPV1APP
SCHEMBL1480230 0.97 MAPT (0.43) MAPTKDM4ETDP1TRPV1APP
SCHEMBL1480232 0.97 MAPT (0.43) MAPTKDM4ETDP1TRPV1APP
SCHEMBL6531606 0.95 MAPT (0.38) MAPTKDM4ETDP1TRPV1APP
SCHEMBL6531603 0.95 MAPT (0.38) MAPTKDM4ETDP1TRPV1APP
SCHEMBL1481772 0.92 ATP4A (0.45) AHRSMN1; SMN2ATP4AATP4B
SCHEMBL1481771 0.92 ATP4A (0.45) AHRSMN1; SMN2ATP4AATP4B
SCHEMBL1481070 0.88 MAPT (0.44) MAPTKDM4ERELAMAOBAHR
SCHEMBL1481066 0.88 MAPT (0.44) MAPTKDM4ERELAMAOBAHR
SCHEMBL1480854 0.86 BACE1 (0.51) XDHKCNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
EP-1594847-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS Transtech Pharma, Inc. (US) 2005-11-16 EP disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed
WO-2004071447-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC. (US) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ MAPT 3558/4885KDM4E 672/4885TDP1 1423/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ MAPT 3558/4885KDM4E 672/4885TDP1 1423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.